Abstract: The present invention relates to an application of an artemisinin compound in treatment of coronavirus infection. Specifically, the present invention provides an application of the compound, and a stereoisomer, a pharmaceutically acceptable salt, a solvate or a hydrate thereof in preparation of medicines. The medicines are used for treating diseases or infection caused by coronavirus (preferably SARS-CoV-2), and the compound is selected from one or more of artemisinin, arteether, artemether, artemisia ketone, dihydroartemisinin, artesunate, arteannuin B, and artemisinic acid.

Abstract: The present application provides an ultrasonic wake-up system. The system includes an ultrasonic imaging device, an ultrasound stimulation device, and an ultrasound stimulation effect evaluation device, and acquires an ultrasonic image of a target object through the ultrasonic imaging device, transmits an ultrasound to the target object based on the ultrasonic image through the ultrasound stimulation device, and adjusts the transmitted ultrasound required through the ultrasound stimulation effect evaluation device. Therefore, peripheral nerves are accurately stimulated, an uplink reticular wake-up system is activated, so as to wake up patients with disorders of consciousness.

Abstract: The technology of this application relates to the field of filter technologies, and provides a common mode filter and a terminal device. The common mode filter includes a first winding and a second winding. A portion of the first winding and a portion of the second winding are formed, by rotating around a same axis, at a first coil layer. The other portion of the first winding and the other portion of the second winding are formed, by rotating around another same axis, at a second coil layer stacked with the first coil layer. At the first coil layer and the second coil layer, there is one turn of the second winding between each two adjacent turns of the first winding.

Abstract: An extrusion device and a 3D printer are provided. The extrusion device includes a feeding mechanism, a discharging mechanism, a first driving mechanism, a switching mechanism and a second driving mechanism. The feeding mechanism includes a first feeding pipe and a second feeding pipe. The discharging mechanism includes a discharging pipe, and the discharging pipe is connected to the first feeding pipe and the second feeding pipe. The first driving mechanism is used for driving a consumable in the first feeding pipe or the second feeding pipe to move. The switching mechanism corresponds to the first feeding pipe and the second feeding pipe, and the second driving mechanism corresponds to the switching mechanism and is used for driving the switching mechanism to switch between a first state and a second state. The working efficiency of the apparatus can be improved.

Abstract: A three-dimensional (3D) memory device includes a memory stack including interleaved a plurality of conductor layers and a plurality of insulating layers extending laterally in the memory stack, a memory block including a plurality of channel structures extending vertically through the memory stack, a plurality of source structures extending vertically and laterally in the memory stack and being in contact with the memory block, and a plurality of conductor portions and a plurality of insulating portions being interleaved and locating between two adjacent source structures along a direction which the source structure extends. The interleaved plurality of conductor portions and plurality of insulating portions are each in contact with corresponding conductor layers and corresponding insulating layers of the same level from adjacent memory blocks.

Abstract: A chimeric antigen receptor containing a CD3? intracellular region with a Y/F mutation, includes an extracellular domain, a transmembrane domain, and an intracellular domain which are connected in sequence, where one end of the intracellular domain, which is connected to the transmembrane domain, is connected to the CD3? intracellular region with the Y/F mutation, and the CD3? intracellular region with the Y/F mutation refers to a Y/F mutant CD3? intracellular region in which both tyrosines are mutated to phenylalanines in the ITAM of the CD3? intracellular region. T cells modified with the chimeric antigen receptor have improved viability, decreased apoptosis level, and increased proliferation ability, and down-regulate the expression levels of cytokines IFN-? and TNF-?.

Abstract: A semiconductor device assembly, comprising a first semiconductor device including a first substrate with a frontside surface, a plurality of solder bumps located on the frontside surface of the first substrate, and a first polymer layer on the frontside surface. The semiconductor device assembly also comprises a second semiconductor device including a second substrate with a backside surface, a plurality of TSVs protruding from the backside surface of the second substrate, and a second polymer layer on the backside surface of the first substrate, the second polymer layer having a plurality of openings corresponding to the plurality of TSVs. The first and second semiconductor devices are bonded such that the first polymer layer contacts the second polymer layer and each of the plurality of solder bumps extends into a corresponding one of the plurality of openings and contacts a corresponding one of the plurality of TSVs.

Abstract: A micro-syringe for inserting into a sample matrix. The micro-syringe includes a micro-syringe body having an orifice at an insertion end; and a plunger at least partially coated with a solid-phase micro-extraction (SPME) coating. The plunger is longitudinally movable between an internal position and an extended position. When the syringe is inserted into the sample matrix, the extraction phase is shielded from the sample matrix by the micro-syringe body when the plunger is in the internal position, and at least a portion of the extraction phase extends past the orifice and is exposed to the sample matrix when the plunger is in the extended position. The plunger is sized to fit the internal diameter of the micro-syringe body to draw a liquid into the micro-syringe body when the plunger is moved from the extended position to the internal position.

Abstract: A preparation method for glufosinate ammonium or a salt thereof, an enantiomer thereof, or mixtures of the enantiomer thereof in all ratios, comprising reacting a compound of formula (II) or a salt, an enantiomer, or mixtures of the enantiomer in all ratios with one or more compounds of formula (III) or mixtures thereof.

Abstract: Provided is an ST2 antigen binding protein, such as a mouse, human, chimeric or humanized antibody or antigen binding fragment thereof that specifically binds to ST2. Also provided are nucleic acid molecules encoding the above-mentioned antibodies and antigen binding fragments thereof, and an expression vector and host cell for expressing the antibodies or antigen binding fragments thereof. Further provided are methods for preparing and using the antibodies and antigen binding fragments thereof. The methods comprise treating and preventing IL33/ST2-mediated related diseases or conditions.

Abstract: A ripple detection device and a ripple suppression device. The ripple detection device includes: a ripple sampling unit, at least two DC sampling units, and a digital signal processing unit; the ripple sampling unit outputs a first voltage signal at an output port of a non-isolated DC/DC bidirectional energy conversion unit to the digital signal processing unit; the DC sampling unit outputs a first DC signal in a second voltage signal at a connected port of the non-isolated DC/DC bidirectional energy conversion unit to the digital signal processing unit and blocks an AC signal in the second voltage signal to be output to the digital signal processing unit; the digital signal processing unit determines a ripple noise signal at the output port of the non-isolated DC/DC bidirectional energy conversion unit according to the first voltage signal and the first DC signal.

Abstract: Examples herein involve estimating a first position of a mobile device based on first communication signals, assigning a first set of particles to a number of respective first sampling locations within a threshold distance of the first position, adjusting the assignment of the first set of particles to second sampling locations based on movement of the mobile device, and estimating a second position of the mobile device based on the second sampling locations.

Abstract: Disclosed are a method and an apparatus for controlling multileaf collimator in radiotherapy. The method comprises: acquiring a preset model; outputting, regarding a radiotherapy target, a target leaf sequence of a multileaf collimator through the preset model, to obtain a planning file; and importing the planning file into a radiotherapy planning system to control a linear accelerator to operate, so as to implement a radiotherapy plan, which solves the technical problem in the related art of poor accuracy and stability in determining a leaf sequence of a multileaf collimator.

Abstract: A method for preparing a ceramic copper clad laminate is provided, including following steps: providing a copper material; forming a copper oxide layer on a surface of the copper material; thermally treating the copper material on which the copper oxide layer is formed, to diffuse oxygen atoms in the copper material; removing the copper oxide layer on the thermally treated copper material; and soldering the copper-oxide-layer-removed copper material to a ceramic substrate to obtain a ceramic copper clad laminate.

Abstract: The present invention relates to an application of benflumetol and derivatives thereof in treatment of coronavirus infection, and specifically provides uses of a compound represented by formula A, and a stereoisomer, a pharmaceutically acceptable salt, a solvate or a hydrate thereof in preparation of drugs. The drugs are used for treating diseases or infection caused by coronavirus (preferably SARS-CoV-2).

Abstract: The present invention relates to a method for preparing glufosinate or an analogue and an intermediate thereof. The method comprises: a) reacting a compound of formula (II), an alcohol of formula (III) and a compound of formula (V); and b) hydrolyzing the product of the reaction above to obtain glufosinate of formula (IV) or an analogue thereof.

Abstract: The embodiments of the present disclosure provide a method for analyzing a body fluid proteome. The method comprises: obtaining a sample to be tested I enriched with low-abundance proteins by removing high-abundance proteins in an initial sample A using an affinity technique; obtaining a sample to be tested II enriched with low-abundance proteins by removing high-abundance proteins in an initial sample B using chemical precipitation, wherein the initial sample A and the initial sample B are obtained from a same body fluid sample of a same subject; obtaining a proteome data set I by performing proteomic analysis on the sample to be tested I; obtaining a proteome data set II by performing proteomic analysis on the sample to be tested II; and determining a final quantified proteome data set of the body fluid sample based on the proteome data set I and the proteome data set II.

Abstract: A semiconductor device having monolithic conductive cylinders, and associated systems and methods, are disclosed herein. The semiconductor device can include a semiconductor substrate, a conductive pad, an opening, and a top dielectric layer. The conductive pad may be at a first surface of the semiconductor substrate. The opening may be ring-shaped and extend through the semiconductor substrate from the conductive pad to a second surface and define a side wall. The liner may coat the side wall and the top dielectric layer may cover the second surface and may fill the opening. A second ring-shaped opening may be formed through the semiconductor device and the opening and a conductive material plated therein.

Abstract: The present invention relates to a method for preparing glufosinate or analogues thereof.

Abstract: The present disclosure provides a marker and use thereof in predicting a possibility of a subject with diabetes. The marker described may include at least one of ?-hydroxybutyric acid (?-HB), 1,5-anhydroglucitol (1,5-AG), asymmetric dimethylarginine (ADMA), cystine, ethanolamine, taurine, L-leucine, L-tryptophan, hydroxylysine, and L-aspartate. The possibility of the subject with diabetes may be predicted using a prediction model (e.g., prediction models 2-5) related to the marker based on a concentration of the marker. The prediction model 2 is related to ?-HB. The prediction model 3 is related to 1,5-AG and ADMA. The prediction model 4 is related to cystine, ethanolamine, taurine, L-leucine, L-tryptophan and hydroxylysine. The prediction model 5 is related to ?-HB, 1,5-AG, cystine, ethanolamine, taurine and L-aspartate.